本文選題：氧化應(yīng)激 + 白細(xì)胞介素17　； 參考：《重慶醫(yī)科大學(xué)》2011年碩士論文

【摘要】：目的 研究細(xì)胞因子白細(xì)胞介素17(interleukine-17,IL-17)在Graves眼病(Graves' ophthalmopathy,GO)發(fā)病中的作用,并探討氧化應(yīng)激與IL-17的關(guān)系。 方法 25例初發(fā)活動(dòng)期的Graves眼病病人作為GO組,15例健康人作為對(duì)照組納入研究。臨床評(píng)估GO病人眼病活動(dòng)度(clinical activity score,CAS)及嚴(yán)重度(NOSPECS))。每位入選者均采集外周血,檢測(cè)血清中游離三碘甲腺原氨酸(free triiodothyronine,FT3 )、游離四碘甲腺原氨酸(free tetraiodothyronine,FT4)、超敏促甲狀腺激素(hypersensitive thyroid-stimulating hormone,μTSH)、甲狀腺球蛋白抗體(thyroglobulin antibody,TgAb)、甲狀腺過(guò)氧化物酶抗體(thyroid peroxidase antibody,TPOAb)、促甲狀腺激素受體抗體(thyrotrophin receptor antibody ,TRAb)以及IL-17、丙二醛(monohydrate ,MDA)水平和超氧化物歧化酶(superoxide dismutase ,SOD)活力。 從對(duì)照組和GO組中各選取10例,采外周血。分離T淋巴細(xì)胞,體外與過(guò)氧化氫(Hydrogen Peroxide Solution,H2O2)和/維生素C(Vitamin C,Vitc)共同培養(yǎng)。每例標(biāo)本的T淋巴細(xì)胞均分組為:空白組(H2O2 =0,VitC =0),過(guò)氧化氫組(H_2O_2 =1 000 nM,VitC=0),維生素C組(H_2O_2 =0,VitC =25μM),過(guò)氧化氫+維生素C組(H_2O_2 =1000 nM,VitC=25μM),檢測(cè)細(xì)胞培養(yǎng)上清液IL-17水平,并進(jìn)行統(tǒng)計(jì)分析。 結(jié)果 1.GO病人眼病活動(dòng)度評(píng)分均≥3分(范圍3-6,均值4.88±0.93),嚴(yán)重度NOSPECS≥3級(jí)(范圍3-5,均值3.56±0.65)。 2.與對(duì)照組相比,GO組血清FT3(13.49±4.96 vs. 3.11±0.16 pg/ml),FT4(6.03±2.64 vs.1.24±1.36 ng/dl),TPOAb(300.38±233.05 vs.44.20±37.51 IU/ml),TgAb(1542.54±1614.51 vs.59.52±34.66 IU/ml),TRAb(19.41±3.77 vs.12.47±1.15U/L)及IL-17(13.62±2.43 vs. 10.15±0.93ng/L)水平較正常顯著升高(P㩳0.01或P㩳0.05),μTSH (0.02±0.02 vs.1.24±0.14 mIU/L)顯著降低(P㩳0.01),年齡無(wú)顯著差異(30.00±5.30 vs.31.04±8.33歲)(P㧐0.05)。GO血清IL-17與眼病臨床活動(dòng)評(píng)分CAS(r=0.43,P=0.03)正相關(guān),與嚴(yán)重度無(wú)相關(guān)。 3.GO組血清MDA較對(duì)照組(6.77±1.11 vs. 4.16±0.61nmol/ml)顯著升高(P㩳0.05),SOD活力(53.95±17.53 vs. 73.16±15.33U/ml)顯著降低(P㩳0.05)。GO組血清MDA水平與IL-17呈顯著正相(r=0.490,P=0.046);MDA水平、SOD活力與眼病臨床活動(dòng)評(píng)分和嚴(yán)重度均無(wú)相關(guān)性(P㧐0.05)。 4 T淋巴細(xì)胞培養(yǎng)上清液IL-17水平檢測(cè)分析,GO組中T淋巴細(xì)胞的H2O2組(27.55±4.75 ng/L)㧐空白組(20.24±2.13 ng/L )㧐VitC(18.76±1.13 ng/L)組及H2O2+VitC(17.59±1.85 ng/L)組(P㩳0.05);VitC組及H2O2+VitC組間無(wú)顯著差異(P㧐0.05)。對(duì)照組的T淋巴細(xì)胞各組間無(wú)顯著差異(P㧐0.05)。 結(jié)論 1.初發(fā)活動(dòng)期GO病人外周血IL-17顯著升高,并與CAS相關(guān),可能參與了GO的發(fā)病; 2.氧化應(yīng)激參與了GO病人IL-17水平的上調(diào)。VitC可在一定程度減少IL-17釋放,為臨床補(bǔ)充抗氧化劑作為GO輔助治療提供思路和依據(jù)。
[Abstract]:Objective to investigate the role of interleukine-17 (IL-17) in the pathogenesis of Graves' ophthalmopathy (Graves' ophthalmopathy go) and to explore the relationship between oxidative stress and IL-17. Methods 25 patients with Graves' ophthalmopathy in the first active stage were included in the study as the go group and 15 healthy persons as the control group. Clinical evaluation of (clinical activity scorex and NOSPECS). In patients with go Each candidate collected peripheral blood, Serum free triiodothyronine (FT3), free tetraiodothyronine (FT4), hypersensitive thyroid-stimulating hormone (渭 TSH), thyroglobulin antibody-TgAb (TGAb), (thyroid peroxidase antibody TPOAb (TPOAb) and thyrotropin receptor (TPOAb) were detected. The levels of (thyrotrophin receptor antibody, IL-17, malondialdehyde (monohydrate) and the activity of superoxide dismutase (superoxide dismutase) were observed. Peripheral blood was collected from 10 cases in control group and 10 cases in go group. T lymphocytes were isolated and co-cultured with hydrogen peroxide (H _ 2O _ 2) and vitamin C (Vitamin C) in vitro. The T lymphocytes of each specimen were divided into three groups: blank group (H _ 2O _ 0 / Vit _ C _ (0), H _ 2O _ 2 / T _ 2 (H _ 2O _ 2 / 1 000 nM ~ (vit) C _ (10), Vitamin C _ (25 渭 M), H _ 2O _ 2O _ 2 / S (H _ 2O _ 2O _ 2 / M Vitamin C ~ (25 渭 M) and H _ 2O _ 2 / V _ 2O _ 2 vitamin C ~ (2 +) group (H _ 2O _ 2 / M ~ (2 000) N ~ (VitC) ~ (25 渭 M). Results 1. The scores of eye motion were 鈮，

本文編號(hào)：2083369